Continued strong growth of ZORYVE ® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing...
WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children...
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approved...
WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved...
Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical...
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can...
 Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food...
WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...